← Eichor
Study identifier: NCT07248930 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Thermal Burns

Condition: Burns  ·  Sponsor: Efferon JSC

PhaseN/A
Planned participants30
Who can joinAll sexes, 1 Year to 14 Years
Healthy volunteersNo

About this study

This observational pilot study aims to identify criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS NEO device in pediatric burn injury. Participants will be prospectively assigned to the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with an interval of 24-120 hours between procedures. The sessions may be performed in combination with hemofiltration or hemodiafiltration at the discretion of the investigator.

This description comes directly from the study's public registry record.

Talk to the study team

Alexandr Shelehov-Kravchenko, PhD, MD  ·  +79636564765  ·  alexandr.shelehov@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

Children's City Clinical Hospital No. 9 named after G.N. Speransky of the Moscow City Health DepartmentMoscow, RussiaRecruiting
Children's municipal multi-specialty clinical center of high medical technologySaint Petersburg, RussiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07248930